Trial Group - Gastrointestinal

Hepatocellular Carcinoma

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation (KEYNOTE-937).

Metastatic colorectal cancer (bowel cancer) that is unresectable and not suitable for intensive therapy

The main purpose of the study is to determine if S95005 in combination with bevacizumab is better than capecitabine with bevacizumab for progression free survival in mCRC patients who have not received any treatment for metastatic disease yet and are not suitable for intensive chemotherapy

This study is for patients with hepatocellular cancer (type of liver cancer) which has spread (metastasised)

To compare the safety and efficacy between the two groups in this study – those treated with Lenvatinb and Pembrolizumab and those treated with Lenvatib alone.

Previously untreated HER2 negative advanced cancer of the stomach or the junction between the stomach and the oesophagus (gastrooesophageal junction).

This trial will compare the effectiveness of a drug called Pembrolizumab used in combination with chemotherapy, to a placebo used in combination with chemotherapy.

Patients will be randomly assigned (randomised) between either Pembrolizumab and chemotherapy, or placebo and chemotherapy.

Cancer of the oesophagus or gastro-oesophageal junction which has spread (metastasised).

To compare survival between the two groups – those treated with Trastuzumab, chemotherapy and Pembrolizumab and those treated with Trastuzumab, chemotherapy and placebo.

Patients with cancer of the colon which has spread (metastasised).

To find and test new stratification tools (ways of dividing patients into different groups) in patients who have microsatellite stable RAS mutant metastatic colorectal cancer.

Cancer of the rectum.

The purpose of this trial is to compare two radiotherapy techniques for treating locally advanced rectal cancer.

Pancreatic cancer

The purpose of this trial is to investigate how proteins and genes respond to pancreatic cancer treatment.

Colorectal cancer (colon or rectal)

The purpose of this trial is to investigate what proteins and genes are related to the recurrence of colorectal cancer.

Cancer of the oesophagus or the junction between the oesophagus and the stomach.

The aim of this trial is to compare and evaluate two well-established standard of care treatments for cancer of the oesophagus in order to establish if one treatment is better than the other.